11th Apr 2023 14:10
MGC Pharmaceuticals Ltd - Perth, Australia-based pharmaceutical company specialising in plant-inspired medicines - Says its investigational medicinal product CannEpil for patients suffering from refractory epilepsy is now available in the UK by named patient request to be prescribed by doctors. The product is now in the process of a clinical development programme.
Says CannEpil was made available in 2019 for distribution and prescription in Ireland under full governmental health insurance coverage. Epilepsy is one of the most common, serious neurological conditions.
Additionally, raises GBP1.2 million in a placing of 274.4 million shares at 0.44 pence each.
Chief Executive Officer Roby Zomer says: "This fundraise will provide MGC Pharma with the capital required to continue the excellent progress we have made advancing our clinical pipeline."
Current stock price: 0.45 pence each, down 18% on Tuesday afternoon in London
12-month change: down 66%
By Xindi Wei, Alliance News reporter
Comments and questions to [email protected]
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Related Shares:
MXC.L